

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Crizotinib, a targeted agent recently approved for use in the treatment of ALK-positive NSCLC, was recently shown to also exhibit antitumor activity in patients with NSCLC harboring ROS1 gene rearrangement.
  - a. True
  - b. False
2. The Phase III LUX-Lung 3 trial evaluating afatinib versus cisplatin/pemetrexed as first-line therapy for patients with advanced EGFR-mutant NSCLC reported improvements in which of the following for patients who received afatinib?
  - a. Median PFS
  - b. Median duration of response
  - c. Objective response rate
  - d. Both a and c
  - e. All of the above
3. Favorable responses have been reported with the anti-PD-1 antibody in patients with \_\_\_\_\_ NSCLC.
  - a. Adenocarcinoma
  - b. Squamous cell
  - c. Neither a nor b
  - d. Both a and b
4. The addition of selumetinib to docetaxel in the second line significantly prolonged PFS compared to placebo in a Phase II trial for patients with \_\_\_\_\_ advanced NSCLC.
  - a. EGFR-mutant
  - b. K-ras-mutant
  - c. BRAF-mutant
5. In a Phase II trial of afatinib with cetuximab for patients with NSCLC and acquired resistance to erlotinib or gefitinib, investigators reported confirmed responses in \_\_\_\_\_.
  - a. T790M mutation-positive disease
  - b. T790M mutation-negative disease
  - c. Both a and b
  - d. Neither a nor b
6. A Phase II trial evaluating carboplatin, nab paclitaxel and bevacizumab for patients with untreated advanced nonsquamous NSCLC reported a near 75% disease control rate with this combination.
  - a. True
  - b. False
7. The Phase II SELECT study evaluating adjuvant \_\_\_\_\_ for patients with resected EGFR mutation-positive NSCLC reported a disease-free survival rate of 94% after more than 2 years of follow-up.
  - a. Afatinib
  - b. Erlotinib
  - c. Gefitinib
8. The Phase III MetLung study will investigate \_\_\_\_\_ with erlotinib versus placebo with erlotinib for patients with advanced MET-positive NSCLC.
  - a. Tivantinib
  - b. Onartuzumab
  - c. Gefitinib
9. The AVAPERL trial demonstrated that the addition of pemetrexed to maintenance therapy with bevacizumab significantly increased PFS for patients with advanced nonsquamous NSCLC.
  - a. True
  - b. False
10. Final analysis of overall survival in the PARAMOUNT study demonstrated a significant increase in overall survival with the addition of pemetrexed to best supportive care for patients with advanced nonsquamous NSCLC.
  - a. True
  - b. False